To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their ...

A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...

Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight ...

Eli Lilly has reduced the prices of certain Zepbound vials and introduced higher-dose options, making the weight-loss drug ...

This month pharmacies will no longer be allowed to sell lower-cost compounded versions of the anti-obesity drug tirzepatide — ...

Mounjaro (tirzepatide) is a brand-name injection prescribed for type 2 diabetes in adults. As with other drugs, Mounjaro can cause side effects, such as nausea, diarrhea, and appetite loss.

Wegovy (semaglutide) and Mounjaro (tirzepatide) are brand-name injections. Wegovy is prescribed for weight loss and to lower cardiovascular risks. Mounjaro is approved for type 2 diabetes ...

The semaglutide shortage has officially ended in the US—which means the GLP-1 drug industry is about to undergo massive changes.

On March 5, 2025, the U.S. District Court for the Northern District of Texas denied the Outsourcing Facilities Association’s motion for a ...

The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper compounded versions ...

A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy of the weight-loss medicines it mailed to patients.